IDH野生型胶质瘤的治疗差异:手术与辅助治疗的影响
多中心回顾性研究对比160例IDH野生型星形细胞瘤与203例IDH野生型胶质母细胞瘤,发现星形细胞瘤患者更年轻且总生存更长;星形细胞瘤中切除>50%即可使OS翻倍,>98%可 tripled,而胶质母细胞瘤需>80%才 tripled;星形细胞瘤中MGMT甲基化与生存无关,同步放化疗不优于序贯治疗。
要点
- IDH野生型星形细胞瘤患者较胶质母细胞瘤年轻,总生存显著更长。
- 星形细胞瘤中切除>50%即可延长OS,>98%可 tripled。
- 星形细胞瘤中同步放化疗不优于序贯治疗,最大安全切除更重要。
核心结论
- IDH野生型星形细胞瘤临床病程不同于IDH野生型胶质母细胞瘤,发病早且生存更长。
- 星形细胞瘤中同步放化疗不优于序贯治疗,最大安全切除比经典胶质母细胞瘤更重要。
研究设计与样本
- 多中心回顾性分析,6所大学医院2016-2019年数据。
- 纳入160例IDH野生型弥漫性星形细胞瘤(无胶质母细胞瘤组织学特征)患者,37.5%女性。
- 对照为203例IDH野生型经典胶质母细胞瘤患者,43.8%女性。
主要发现
- 星形细胞瘤中位年龄58.1岁,胶质母细胞瘤67.6岁(p<0.0001)。
- 星形细胞瘤平均总生存36.1±15.1个月,胶质母细胞瘤17.9±2.7个月(p<0.0001)。
- 星形细胞瘤中切除>50%影像学肿瘤使OS翻倍,切除>98%使OS tripled。
- 胶质母细胞瘤中需切除>80%肿瘤体积才能使OS tripled。
- 星形细胞瘤中MGMT甲基化与更长生存无关(p=.2124)。
临床怎么用
- 对IDH野生型星形细胞瘤应追求最大安全切除,切除程度>50%即可显著改善生存。
- IDH野生型星形细胞瘤辅助治疗可考虑序贯放化疗而非同步放化疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Isocitrate dehydrogenase (IDH) wildtype (wt) astrocytomas without the microscopic features of glioblastoma have high recurrence rates and were re-classified in the presence of certain molecular features as CNS WHO grade 4 tumors in the latest WHO classification of 2021. This study examines the clinical heterogeneity within this histologically defined group and explores implications for treatment decisions, with particular focus on the role of surgical resection. METHODS: Data acquisition was conducted as a multi-center retrospective analysis at 6 University Hospitals (2016-2019). Patients with IDH-wt diffuse astrocytoma without histological features of glioblastoma were enrolled. Patients presenting with IDH-wt classical glioblastoma from one institution served as controls. Primary outcome parameters were extent of resection (EOR) according to RANO 2.0 criteria, progression-free survival (PFS), and overall survival (OS). RESULTS: 160 patients with IDH-wt astrocytoma (37.5 % females) and 203 patients with IDH-wt glioblastoma (43.8 % females), were enrolled. The median age in patients with astrocytoma was younger (58.1 vs. 67.6 years; p<0.0001). Mean overall survival was significantly longer in astrocytomas (36.1 ±15.1 months) compared to glioblastomas (17.9 ±2.7 months) (p<0.0001). The extent of tumor resection is a significant factor for PFS and OS in both groups. In IDH-wt astrocytoma OS is doubled after resection of more than 50% of radiographic tumor and tripled if resection of >98% is achieved. In IDH-wt glioblastoma, resection of more than 80% of the tumor volume is needed to achieve tripled OS. MGMT methylation was not associated with longer survival in IDH-wt astrocytoma (p=.2124). While concomitant radiochemotherapy (Stupp/CeTeG) was superior to monotherapy in IDH-wt glioblastoma (p=.0094) it is non-superior to sequential therapy (radiotherapy followed by chemotherapy) in IDH-wt astrocytoma (p=.1134). CONCLUSION: The presented data suggests that the clinical course of IDH-wt astrocytoma, is different from IDH-wt glioblastoma with an early onset and longer survival. As concomitant radiochemotherapy is non-superior in IDH-wt astrocytoma, maximum safe resection is even more important than in classical IDH-wt glioblastoma.
引用
- Keric N, Krenzlin H, Lange F, et al. Treatment differences in IDH-wildtype glioma - the impact of surgery and adjuvant therapy. J Neurooncol. 2025. PMID: 41466163. doi:10.1007/s11060-025-05368-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。